DOCSLIB.ORG

Resi Program Final High

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Resi Program Final High redefining eARLY sTAGE iNVESTMENTs RESI 3 Early Stage Life Science Investment Just Hit a Home Run! ONSITE GUIDE September 17, 2014 Fenway Park Boston, MA RESIConference.com #RESI3 LifeScienceNation.com EMC Level FENWAY PARK EMC CLUB 3 LEVEL 3 EMC2 SUITE L2 Exit FIELD VIEW Board Room Exit Exit Stairs/Escalators workshopS TO State st. Bar Area pavilion LEVEL PARTNERING Forum REGISTRATION sTATE sTREET PAVILION Level State Street. PAVILION lEVEL 4 FENWAY PARK pRESS ROOM mEDIA dINING TRACK 2 TRACK 1 Exit 13 1 2 12 1 FIELD VIEW 2 12 3 Exit Exit 11 11 3 4 10 10 4 5 5 6 6 7 7 8 9 9 8 15 25 16 25 16 26 32 17 30 17 26 27 28 29 30 31 18 24 27 28 29 18 Stairs/Escalators 24 19 23 23 22 22 21 21 20 20 19 13 14 14 15 Bar Area PANELS Exhibiting companies TO EMC LEVEL pRESENTING companies contents TABLE OF CONTENTS Welcome from Dennis Ford - - - - - - - 2 RESI Schedule - - - - - - 3 Investor Panels - - - - - - - 5 Early Stage Workshops - - - - - - 25 Partnering Forum - - - - - - - 26 RESI Innovation Challenge - - - - - - - 27 Exhibiting Companies - - - - - - 29 Sponsors - - - - - - - 30 Media Partners - - - - - - - 33 1 welcome to resi Life Science Nation would like to welcome you to the third Redening Early Stage Investments (RESI) conference. We're excited to see you here at our new landmark location, Fenway Park. I hope you are ready to get the most out of a day lled with content, meetings and opportunities for everyone who has a stake in the early-stage life science sector. While the venue and much of our cutting-edge content may be new, our all-day partnering sessions remain the core of RESI. Face-to-face meetings between entrepreneurs and investors are the most vital part of the fundraising process, and RESI is designed to make that direct contact as productive and as meaningful as possible. The relationships you start at RESI could make your company. Throughout the day we have two tracks of discussion panels, where you can hear from leaders who represent the diversity of the life science investment world today. We also invite you to join our RESI workshops, where you will receive hands-on tactical advice about many aspects of the process of taking your technology towards commercialization. We'd also like to bring your attention to the RESI Innovation Challenge taking place today. To be a part of this virtual investment challenge, meet with the RESI Innovators showcasing their groundbreaking technologies throughout the exhibition hall, and put your 'RESI Cash' toward those that most inspire you. Finally, we'd like to thank you for being here today. Whether you're here today as an early-stage investor or as an entrepreneur developing a breakthrough life science technology, you are a vital part of the RESI community and we're honored that you've made RESI part of your journey from discovery to commercialization. Sincerely, Dennis Ford Founder & CEO Life Science Nation 2 RESI SCHEDULE Track 1: Track 2: Track 3: Track 4: Investor Investor Early Stage Partnering Panels Panels Workshops Forum Media Dining Press Room Suite L2 EMC CLUB 7:00 - 8:00 AM: Registration & Breakfast 8:00 - Point-of-Care aNGEL 8:50 Institution gROUP AM 9:00 - VENTURE PATIENT MORNING 9:50 PHILANTHROPY GROUPS fundraising EARLY STAGE AM bootcamp PARTNERING 10:00 FORUM mEDICAL device - boston 10:50 Strategics AM multi- and single innovation capital family 11:00 offices - Orphan/rare 11:50 disease AM 12:00 - 1:00 PM: Break for Lunch 1:00 - cro OUTBOUND 1:50 direct investment FUNDRAISING THE LIFE SCIENCES PM LEGAL LANDSCAPE 2:00 - bIG NON-PROFIT AFTERNOON 2:50 PHARMA DIRECT INVESTMENT branding & EARLY STAGE PM messaging PARTNERING 3:00 FORUM - VIRTUAL FUNDRAISING 3:50 PHARMA PARTNERS PM 4:00 - CORPORATE vENTURE 4:50 VENTURE CAPITAL CAPITAL PM 5:00 - 7:00 PM: Cocktail Reception State Street Pavilion 3 investor panels Track 1 Track 1 Moderator & Panelists 8:00 - 8:50 AM • Monique Yoakim-Turk, Partner, Technology Development Fund of Boston Children’s Hospital M • Barbara Gamez Sims, Technology Licensing Manager, Mayo Clinic Ventures Point-of-Care • Chris Coburn, VP, Innovation, Partners HealthCare Institution • Kanad Das, Program Manager, Stanford SPARK • Manu Nair, Vice President, Technology Ventures, Oklahoma Medical Research Foundation 9:00 - 9:50 AM • Brian Horsburg, Trustee, NeuroNetworks Fund M • Albert Roy, CEO, Lupus Therapeutics VENTURE • Charlotte Hubbert, Venture Investor, Bill & Melinda Gates Foundation PHILANTHROPY • Daniel Auclair, VP of Translational Research, Multiple Myeloma Research Foundation • Tim Armour, President & CEO, Cure Alzheimer's Fund 10:00 - 10:50 AM • Yuri Haverman, Strategic Innovation, Medical Surgical Systems, Becton Dickinson M • Aaron Sandoski, Co-Founder & Managing Director, Norwich Ventures mEDICAL device • Josh Phillips, Managing Partner, Catalyst Health Ventures Strategics • Juan Carlos Serna, Vice President, HPA Ventures • Lawrence Cho, Senior Director of Corporate Strategy & Business Development, Medtronic 11:00 - 11:50 AM • Peter Saltonstall, President & CEO, The National Organization for Rare Diseases M • Brian Malkin, Partner, McGuireWoods Orphan/rare • Chris Adams, CEO, Cydan • Jean-Marc Quach, Executive Director, The Alpha-1 Project disease • Mark Barrett, VP, Head Strategy & BD, Rare Diseases, Genzyme • Mark Day, Senior Director, Strategic Evaluation, Alexion 1:00 - 1:50 PM • Peter Lee-Armandt, Manager, Life Sciences Advisory, Sathguru M • David Gee, Vice President, Business Development, Cato BioVentures cro direct • Joseph Vacca, Senior Vice President, Early Success Sharing Partnerships, WuXi AppTec investment • Krishna Kodukula, Executive Director, Strategic Development, SRI International • Michael Recny, CEO, Calvert Holdings 2:00 - 2:50 PM • Bill Kohlbrenner, Chief Science Ofcer, Boston Innovation Capital M • Donnie McGrath, VP, Business Development, Bristol-Myers Squibb bIG • Florian Puehler, Alliance Manager, Bayer HealthCare PHARMA • Kara Bortone, Head of Company Sourcing, Janssen Labs, Johnson & Johnson • Richard Brudnick, SVP Corporate Development, Biogen Idec 3:00 - 3:50 PM • Gene Williams, Founder, Virtua M • Andrew Perlman, Managing Director & CMO, Velocity Pharmaceutical Development VIRTUAL • Baiju Shah, CEO, BioMotiv PHARMA • Dennis Goldberg, President, Benu Biopharma • Jarrod Longcor, CBO, Avillion 4:00 - 4:50 PM • Vikas Goyal, Senior Associate, SR One M • Jason Haer, Director of Investments, Sano-Genzyme BioVentures CORPORATE • Marian Nakada, Vice President, Venture Investments, Johnson & Johnson Development Corporation • Mette Agger, Managing Partner, Lundbeckfond Ventures VENTURE CAPITAL • Stephen R. Padgette, Vice President, R&D Research Strategy, Monsanto Company • Tetsuro Iwata, Senior Manager, MP Healthcare Venture Management 5 investor panels Track 2 Track 2 Moderator & Panelists 8:00 - 8:50 AM • Barbara Nelsen, Founder & CEO, Nelsen Biomedical M • Bill Whitaker, Managing Director, Co-Chair Life Science Section, Golden Seeds aNGEL • Brian Frenzel, Member, Band of Angels gROUP • Praveen Tailam, Managing Director, TiE Angels Boston • Stephen M. Nagler, Executive Director, MedPro Investors 9:00 - 9:50 AM • Steve Perrin, CEO & CSO, ALS Therapy Development Institute M • Annette Bakker, President & CSO, Children's Tumor Foundation PATIENT • Joe Camaratta American Heart Association • Monica Gow, Executive Director, Wake Up Narcolepsy GROUPS • Steven Young, President & COO, Addario Lung Cancer Medical Institute 10:00 - 11:30 AM • Bill Brah, Founder & Executive Director, UMass Venture Development Center M • Alejandra Paredones, CEO & Founder, BSI Capital Group multi- • Christopher de Souza, Director, Broadview Ventures and • Melissa Krauth, Principal, Claria Bioscience single • Meredith Fisher, Director & Partner Investments, family • Todd Holmes, Director, Gurnet Point Capital offices 1:00 - 1:50 PM • Rick Berenson, CEO, Thermalin Diabetes M • Fred Colen, President & CEO, BeneChill OUTBOUND • Gabor Bethlendy, CCO & Founder, Parabase Genomics FUNDRAISING • Michael Tippie, CEO, TomegaVax • Richard Gauthier, Head of Business Development, Microbiotix 2:00 - 2:50 PM • David Sandak, Vice President, Strategy & Research, Accelerate Brain Cancer Cure M • Benjamin Seckler, Founder & President, Charley's Fund NON-PROFIT • Howard Fillit, Executive Director & CSO, Alzheimer's Drug Discovery Foundation DIRECT INVESTMENT • Keting Chu, VP, Research TAP, The Leukemia & Lymphoma Society • Salvatore La Rosa, Senior Director of Research and Development, Children's Tumor Foundation 3:00 - 3:50 PM • Colin Widen, CEO, Boston Innovation Capital M • Adam Cutler, Managing Director, Trout Group FUNDRAISING • Dan Ross, CEO, IMS Health Capital PARTNERS • John Cullity, Partner, Torreya Partners • Paul Papi, Director, Investment Banking, Freedom Investors Corporation 4:00 - 4:50 PM • Bernadette Adamo, Director, Northeast Healthcare/Life Sciences, Silicon Valley Bank M • Jayson Punwani, Associate, Pappas Ventures vENTURE • Jerel Davis, Operating Partner, Versant Ventures CAPITAL • Kiran Reddy, Associate Partner, Third Rock Ventures • Tom Needham, Managing Director, Synthesis Capital 7 McGuireWoods LLP is proud to sponsor Life Science Nation and the 2014 Redefining Early Stage Investments Conference Our commitment to providing clients with quality work and personalized service has allowed us to become a This commitment includes delivering exceptional value, using technology to provide effective legal solutions and employing a diverse workforce to bring real world and innovative perspectives to our life sciences clients. Brian J. Malkin, Senior
Load more

Recommended publications
  • Annual Report
    Fiscal Year 2015 Annual Report To: Governor Charlie Baker Secretary of Administration and Finance Kristen Lepore Secretary of Housing & Economic Development Jay Ash Senate President Stan Rosenberg Speaker of the House Robert DeLeo State Comptroller Thomas G. Shack III Clerk of the Senate William Welch Clerk of the House of Representatives Steven James By forward: House and Senate Committees on Ways and Means and the Joint Committee on Economic Development and Emerging Technologies Date: September 30, 2015 Re: FY 2015 Annual Report of the Massachusetts Life Sciences Center The Massachusetts Life Sciences Center (MLSC) respectfully submits this Annual Report detailing the organization’s operations and accomplishments during Fiscal Year (FY) 2015. For the past seven years, the MLSC has led the state’s life sciences initiative – a $1 billion initiative designed to strengthen the state’s economy by accelerating the growth of our life sciences sectors in Massachusetts. The MLSC’s goal has been to make Massachusetts the strongest life sciences ecosystem in the world and the best place in the world for life sciences companies to do business. The MLSC collaborates with the private sector to accelerate the pace of innovation and economic development in all regions of Massachusetts. The MLSC’s strategy has been based on the belief that the best role for the state is to invest in Massachusetts’ innovation capacity – the ability to produce and commercialize a flow of innovative life sciences technologies over the long term. Since 2008, the MLSC has invested aggressively in five “enablers” that build innovation capacity: translational research, entrepreneurship, workforce development, infrastructure and collaboration.
    [Show full text]
  • View Annual Report
    GENOCEA BIOSCIENCES, INC. FORM 10-K (Annual Report) Filed 02/27/15 for the Period Ending 12/31/14 Address 100 ACORN PARK DRIVE CAMBRIDGE, MA 02140 Telephone 617-876-8191 CIK 0001457612 Symbol GNCA SIC Code 2836 - Biological Products, Except Diagnostic Substances Fiscal Year 12/31 http://www.edgar-online.com © Copyright 2015, EDGAR Online, Inc. All Rights Reserved. Distribution and use of this document restricted under EDGAR Online, Inc. Terms of Use. Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36289 Genocea Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 51 -0596811 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 100 Acorn Park Drive Cambridge, Massachusetts 02140 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (617) 876-8191 Securities registered pursuant to Section 12(b) of the Act: Name of each exchange on which Title of each class registered Common Stock, $0.001 par value NASDAQ Global Market Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
    [Show full text]
  • Annual Report
    HUMAN CAPITAL FISCAL YEAR 2019 ANNUAL REPORT INNOVATION CAPITAL GROWTH CAPITAL INTELLECTUAL CAPITAL The capital of scientific revolution. Fiscal Year 2019 Annual Report • Massachusetts Life Sciences Center • i BOARD OF DIRECTORS TABLE OF CONTENTS A LETTER FROM THE INTERIM PRESIDENT & CEO Michael J. Heffernan Co-Chair; Secretary, Executive Office for Administration & Finance A Letter from the President & CEO ...........................................................................................1 Mike Kennealy Co-Chair; Secretary, Executive Office Vision & Strategy: The Capital of Scientific Revolution ......................................................2 The Patients Are Waiting of Housing & Economic Development Fiscal Year 2019 Highlights and The Bottom Line ..............................................................3 Gary P. Kearney, MD Around the globe, billions of patients and their loved ones await advances in health President, Longwood Urological Associates Human Capital care that will produce the products, devices, and therapies to alleviate suffering, Marty Meehan Internship Challenge: Enhancing Career Exploration improve treatment, and save lives. Much of that attention falls on Massachusetts, as President, University of Massachusetts and Expanding the Talent Pipeline ............................................................................................4 the world looks to our ecosystem to deliver the breakthroughs that further unlock our Peter Parker understanding of human physiology, harness the power of data science,
    [Show full text]
  • Science-USA (Boston+), November 2012
    Schweizerische Eidgenossenschaft Confédération suisse Confederazione Svizzera Confederaziun svizra Science-USA (Boston+), November 2012 Table of Contents 1. Policy ........................................................................................................................................................................................ 1 2. Education .................................................................................................................................................................................. 2 3. Life Science .............................................................................................................................................................................. 3 4. Nano / Micro Technology / Material Science ............................................................................................................................. 4 5. Information & Communications Technology ............................................................................................................................. 6 6. Energy / Environment ............................................................................................................................................................... 6 7. Engineering / Robotics / Space ................................................................................................................................................. 8 8. Physics / Chemistry / Math ......................................................................................................................................................
    [Show full text]
  • LIVIO VALENTI CV 2011-Present VAXESS TECHNOLOGIES, INC
    LIVIO VALENTI CV Livio Valenti is the co-founder of Vaxess Technologies and Giorgio Ruffolo Research Fellow in the Sustainability Science Program at Harvard Kennedy School of Government and the Harvard Global Health Institute. He received a Master in Public Policy from Harvard’s Kennedy School of Government in 2013, where he was the recipient of the Empedocle Maffia Fellowship provided by the Italian Government to one outstanding individual to attend Harvard. While a student at Harvard, he co-founded Vaxess Technologies, an innovative life sciences company that aims to create vaccines that do not need refrigeration. Vaxess has raised $4.75m in venture capital, angel investors, and various public institutions, including the Massachusetts Life Science Center (MLSC). Harvard Business School (HBS) published a case on Vaxess in 2014. Livio was named by Forbes one of the 30 under 30 individuals likely to change the world for his commitment in improving global health and one of the 10 under 40 (PrimiDieci-Under40 2014) most distinguished individuals with Italian origins or Italian nationality currently in the USA by the Italian-American Chamber of Commerce and the Italian Ministry of Foreign Affairs. His academic research at Harvard focuses on the space at the intersection between Government and Business. Livio is researching the potential to sustainably commercialize innovative technologies to improve global health. He is contributing to collaborative work with the Initiative on Innovation and Access to Technologies for Sustainable Development led by William Clark. Professional experience Prior to studying at Harvard, Livio worked for the United Nations in several developing countries. His work included advising government clients and international financing institutions in the identification, appraisal and financing of large investment projects.
    [Show full text]
  • Genocea Biosciences, Inc. (Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material under §240.14a-12 Genocea Biosciences, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): ☒ No fee required. o Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the (3) filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: o Fee paid previously with preliminary materials. Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee o was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: 1 Genocea Biosciences, Inc.
    [Show full text]
  • RENT a BENCH Biotech Incubators Such As Labcentral Are Lowering Barriers to Entrepreneurship by Trisha Gura, in Cambridge, Massachusetts
    NEWS | FEATURES | ENTREPRENEURSHIP GOT A STARTUP? RENT A BENCH Biotech incubators such as LabCentral are lowering barriers to entrepreneurship By Trisha Gura, in Cambridge, Massachusetts ith its cookie-cutter windows and square-meter facility, now owned by the boxy brick exterior, the build- Massachusetts Institute of Technology ing here on Main Street could be (MIT) and leased to LabCentral, functions just another former 19th century as a life science “incubator” that helps bud- W warehouse or factory. It’s no sur- ding biotech firms combat the soaring costs prise to learn that passenger rail- of lab space and equipment in the red-hot road cars were once built in its spacious Boston-Cambridge region. Any scientist on June 11, 2015 interior. Yet the Cambridge landmark has with an idea and ambition can rent a bench a history not just of production, but also and an office, sharing space, services, and of innovation. In 1876, it housed the office high-cost tools with others pursuing their of Thomas Watson, assistant to Alexander own entrepreneurial dreams. “It is very ex- Graham Bell, when the pair made the first citing because we are there at the nascent two-way long-distance phone call, to Bos- moment of many really, really cool com- ton. In the 20th century, it was home to Po- panies,” says molecular biologist Johannes laroid and the lab of Edwin Land when he Fruehauf, a LabCentral founder. invented the instant camera. It’s also the nascent moment for facili- www.sciencemag.org Today, a nonprofit organization called ties like LabCentral.
    [Show full text]
  • Class of 2013 Employment Overview 76
    HARVARD KENNEDY SCHOOL 617-495-1161 [email protected] www.hks.harvard.edu/career CAREER ADVANCEMENT t t t EMPLOYMENT OVERVIEW Class of 2013 HARVARD KENNEDY SCHOOL t CLASS OF 2013 EMPLOYMENT OVERVIEW This overview reflects the diverse employment choices of Harvard Kennedy School (hks) class of The following report on the class of 2013 May graduates immediately post-graduation. 2013 is based on data collected from The Kennedy School degrees continue to show May through October 2013. The hks resilience in an uncertain economy, with our Office of Career Advancement (oca) employed a variety of data collection graduates settling around the globe and across techniques including an exit survey sectors and industries. We invite you to read taken at graduation, a follow-up survey about how our graduates have chosen to serve in September, and individual email inquiries. Overall response rate was 91 the public good through their professional work. percent; of those, 90 percent reported employment or plans to continue in an educational program as of October. OVERVIEW OF GRADUATING 2013 CLASS from 76 539 students countries 242 international MPA/ID MPA2 62 82 12 43 Concurrent/ Concurrent/ Joint Degree Joint Degree MC/MPA MPP 202 193 32 Concurrent/ Joint Degree 87 Concurrent/Joint Degree Students MBA: 69 / Law: 11 / MD: 5 / Divinity: 1 / Design: 1 HARVARD KENNEDY SCHOOL 617-495-1161 [email protected] www.hks.harvard.edu/career CAREER ADVANCEMENT t t t EMPLOYMENT OVERVIEW Class of 2013 HIGHLIGHTS GRADUATES t Eight graduates were selected as t Nonprofit/ngo employment is down IN 2013 finalists in the U.S.
    [Show full text]
  • Fiscal Year 2015 Annual Report
    Fiscal Year 2015 Annual Report To: Governor Charlie Baker Secretary of Administration and Finance Kristen Lepore Secretary of Housing & Economic Development Jay Ash Senate President Stan Rosenberg Speaker of the House Robert DeLeo State Comptroller Thomas G. Shack III Clerk of the Senate William Welch Clerk of the House of Representatives Steven James By forward: House and Senate Committees on Ways and Means and the Joint Committee on Economic Development and Emerging Technologies Date: September 30, 2015 Re: FY 2015 Annual Report of the Massachusetts Life Sciences Center The Massachusetts Life Sciences Center (MLSC) respectfully submits this Annual Report detailing the organization’s operations and accomplishments during Fiscal Year (FY) 2015. For the past seven years, the MLSC has led the state’s life sciences initiative – a $1 billion initiative designed to strengthen the state’s economy by accelerating the growth of our life sciences sectors in Massachusetts. The MLSC’s goal has been to make Massachusetts the strongest life sciences ecosystem in the world and the best place in the world for life sciences companies to do business. The MLSC collaborates with the private sector to accelerate the pace of innovation and economic development in all regions of Massachusetts. The MLSC’s strategy has been based on the belief that the best role for the state is to invest in Massachusetts’ innovation capacity – the ability to produce and commercialize a flow of innovative life sciences technologies over the long term. Since 2008, the MLSC has invested aggressively in five “enablers” that build innovation capacity: translational research, entrepreneurship, workforce development, infrastructure and collaboration.
    [Show full text]
  • What's Inside
    Newsletter A publication of the Controlled Release Society Volume 34 • Number 2 • 2017 What’s Inside Formulation and Delivery of Mono-N-Oxide Vinblastine Liposomal Formulation for Targeting Non-Small Cell Lung Cancer with Hypoxic Environments In Vitro and In Vivo Evaluation of Controlled Payload Release Using Acoustically Responsive Scaffolds CRS Annual Meeting DDTR Update Science. People. Products. Connect and collaborate with delivery science and technology leaders from academia and industry, under one roof at #CRSboston Join us in Boston, Massachusetts, U.S.A. from July 16–19 for the 2017 Controlled Release Society Annual Meeting & Exposition. Registration is now open! Visit controlledreleasesociety.org/CRSboston for details. 2 Newsletter Ryan Donnelly Vol. 34 • No. 2 • 2017 Editor > TABLE OF CONTENTS 4 From the Editor 5 2017 Controlled Release Society Annual Meeting & Exposition Steven Giannos 7 Scientifically Speaking Editor Formulation and Delivery of Mono-N-Oxide Vinblastine Liposomal Formulation for Targeting Non-Small Cell Lung Cancer with Hypoxic Environments 10 Scientifically Speaking In Vitro and In Vivo Evaluation of Controlled Payload Release Using Acoustically Responsive Scaffolds 13 DDTR Update Drug Delivery and Translational Research Update Medha Joshi Editor 14 People in the News 15 Companies in the News Cover image: Malignant effusion: Pleural fluid cytology of lung (pulmonary) papillary adenocarcinoma, a type of non small cell carcinoma. Pap stain. David Litman / Shutterstock.com Arlene McDowell Editor Bozena Michniak-Kohn Editor Rod Walker Editor 3 > FROM THE EDITOR Editors Ryan Donnelly Steven Giannos Steven Giannos Medha Joshi University of Texas Medical Branch Arlene McDowell Galveston, TX, U.S.A. Bozena Michniak-Kohn Rod Walker The CRS Newsletter is the official Please Come to Boston newsletter of the Controlled Release Society.
    [Show full text]
  • Vaxess' Long Road to Heat-Stable Vaccines
    Case Number 2081.0 Technological Innovation for Global Health: Vaxess’ Long Road to Heat-Stable Vaccines It was only April, but 2015 was shaping up to be a busy one for Livio Valenti. The Harvard Kennedy School graduate was named to Forbes’ prestigious “30 under 30” list of the brightest entrepreneurs in science and healthcare, just as Vaxess Technologies, the biotech start-up he co-founded in 2012, was starting to attract atten- tion. Indeed, the company was awarded a research grant from the U.S. National Science Foundation and the U.S. National Institute of Health to put toward the development of heat-stable vaccines—a major honor and accom- plishment, though the grants themselves were modest. Most vaccines had to be refrigerated (or frozen) to preserve their efficacy. However, keeping vaccines at the appropriate temperature from manufacturer to recipient posed significant costs and logistical challenges, especial- ly in many low- and middle-income countries where the majority of the world’s children lived. Valenti believed Vaxess’ technology could provide a potentially simpler, safer approach to heat-stabilizing vaccines from both a scientific and regulatory standpoint—formulating them to withstand a lack of refrigeration—compared to other preservation techniques. In the vaccine field however, the risks and costs of research and development, and lengthy regulatory approval processes were major challenges to advancing products to market. Furthermore, with the greatest need for heat-stable vaccines in developing countries, market incentives for companies to invest in heat-stabilization research and development (R&D) were weak. Still, the U.S. Food and Drug Administration (FDA) had approved silk fibroin—the key ingredient for Vaxess’ platform to heat-stabilize vaccines—for use in medical devices such as surgical sutures and implantable surgical mesh, giving the Vaxess team confidence that their inno- vation would eventually gain FDA approval.
    [Show full text]
  • Vaxess Technologies Closes Final Tranche of $8.2 Million Series a Funding
    Vaxess Technologies closes final tranche of $8.2 million Series A funding 01 July 2019 | News | By Prapti Shah It appoints Dr. Purnanand Sarma to Board Vaxess Technologies, a biotechnology company redefining drug delivery with the silk-powered MIMIX smart release patch has announced it has closed the final tranche of an $8.2 million Series A round. Led by The Engine, the venture capital firm launched by MIT in 2016 to invest in early-stage Tough Tech companies, the round includes participation from Bioinnovation Capital. To date, Vaxess has raised more than $22 million in both grant and equity funding, including backing from the Bill and Melinda Gates Foundation, the National Science Foundation and the National Institutes of Health. Additionally, Vaxess has announced the appointment of drug delivery and development veteran Dr. Purnanand Sarma to the board of directors. Dr. Sarma brings extensive experience in all aspects of the pharmaceutical business. He currently serves as the President and Chief Executive Officer of Immunome, a biotechnology company developing first-in-class therapeutics leveraging the most highly educated components of the immune system from patients. Until recently, he served as the President & CEO of TARIS Biomedical, where he raised more than $100 million in equity financing, drove multiple products into the clinic, and entered into a deal worth up to $587 million with Allergan all based on the company’s proprietary sustained release drug delivery system. Vaxess was born out of technologies developed at MIT and Tufts University where researchers discovered that silk fibroin — an essential structural protein in silk — was an optimal building block for advanced biomaterials.
    [Show full text]